{"ModuleTitle": "Company Description", "CompanyName": "Onconova Therapeutics, Inc.", "Symbol": "ONTX", "Address": "375 PHEASANT RUN, NEWTOWN, Pennsylvania, 18940, United States of America", "Phone": "267-759-3681", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "    Onconova Therapeutics, Inc., sometimes referred to as \"we\" or the \"Company,\"\r\nis a clinical-stage biopharmaceutical company focused on discovering and\r\ndeveloping novel small molecule product candidates primarily to treat cancer. We\r\nhave proprietary targeted agents designed to work against cellular pathways\r\nimportant to cancer cells. We believe that the product candidates in our\r\npipeline have the potential to be efficacious in a variety of cancers. We have\r\none Phase 3 clinical-stage product candidate and two other clinical-stage\r\nproduct candidates (one of which has been studied for treatment of acute\r\nradiation syndromes) and preclinical programs. Substantially all of our current\r\neffort is focused on our lead product candidate, rigosertib.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f27%2f0001047469-20-001878.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Mark P. Guerin", "title": "Chief Financial Officer"}, {"name": "Richard C. Woodman", "title": "Chief Medical Officer, SVP-Research & Development"}, {"name": "Steven M. Fruchtman", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}